Amino acid changes in functional domains of latent membrane protein 1 of Epstein-Barr virus in nasopharyngeal carcinoma of southern China and Taiwan: Prevalence of an HLA A2-restricted 'epitope-loss variant'

Journal of General Virology

Volumn 85, Issue 7, 2004, Pages 2023-2034

  Lin, Jung Chung ^a   Cherng, Jaw Ming ^b   Lin, Hsiung Ju ^c   Tsang, Chi Wai ^d   Liu, Yi Xi ^e   Lee, Steven P ^d  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; EPITOPE; HLA A2 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; VIRUS DNA; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; PEPTIDE FRAGMENT; PRIMER DNA;

AMINO ACID SEQUENCE; ARTICLE; CHINA; CONTROLLED STUDY; DNA ISOLATION; EPSTEIN BARR VIRUS; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HLA TYPING; IMMUNOASSAY; NASOPHARYNX CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROLOGY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TAIWAN; VIRUS STRAIN; AMINO ACID SUBSTITUTION; CHEMISTRY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; RESTRICTION MAPPING; VIROLOGY;

HUMAN HERPESVIRUS 4;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CHINA; DNA PRIMERS; EPITOPES; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; NASOPHARYNGEAL NEOPLASMS; NF-KAPPA B; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; TAIWAN; VARIATION (GENETICS); VIRAL MATRIX PROTEINS;

EID: 3342938562     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.19696-0     Document Type: Article

References (50)

1. Baer, R., Bankier, A. T., Biggin, M. D. & 9 other authors (1984). DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211.
2. Baichwal, V. R. & Sugden, B. (1988). Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2, 461-467.
3. Baichwal, V. R. & Sugden, B. (1989). The multiple membrane-spanning segments of the BNLF-1 oncogene from Epstein-Barr virus are required for transformation. Oncogene 4, 67-74.
4. Chapman, A. L. N., Rickinson, A. B., Thomas, W. A., Jarrett, R. F., Crocker, J. & Lee, S. P. (2001). Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients. Implications for a T-cell-based therapy. Cancer Res 61, 6219-6226.
5. Chen, M. L., Tsai, C. N., Liang, C. L., Shu, C. H., Huang, C. R., Sulitzeanu, D., Liu, S. T. & Chang, Y. S. (1992). Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7, 2131-2140.
6. Cheung, S.-T., Lo, K.-W., Leung, S. F., Chan, W.-Y., Choi, P. H. K., Johnson, P. J., Lee, J. C. K. & Huang, D. P. (1996). Prevalence of LMP1 deletion variant of Epstein-Barr virus in nasopharyngeal carcinoma and gastric tumors in Hong Kong. Int J Cancer 66, 711-712.
7. De Campos-Lima, P.-O., Gavioli, R., Zhang, Q.-J., Wallace, L. E., Dolcetti, R., Rowe, M., Rickinson, A. B. & Masucci, M. G. (1993). HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11 + population. Science 260, 98-100.
8. De Campos-Lima, P.-O., Levitsky, V., Brooks, J., Lee, S. P., Hu, L. F., Rickinson, A. B. & Masucci, M. G. (1994). T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med 179, 1297-1305.
9. de Thé, G. (1982). Epidemiology of Epstein-Barr virus and associated diseases in man. In The Herpesviruses, vol. 1, pp. 25-103. Edited by B. Roizman. New York: Plenum.
10. Devergne, O., Hatzivassiliou, E., Izumi, K. M., Kaye, K. M., Kleijnen, M. F., Kieff, E. & Mosialos, G. (1996). Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol 16, 7098-7108.
11. Duraiswamy, J., Burrows, J. M., Bharadwaj, M., Burrows, S. R., Cooper, L., Pimtanothai, N. & Khanna, R. (2003). Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions. J Virol 77, 7401-7410.
12. Edwards, R. H., Seillier-Moiseiwitsch, F. & Raab-Traub, N. (1999). Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 261, 79-95.
13. Eliopoulos, A. G., Stack, M., Dawson, C. W., Kaye, K. M., Hodgkin, L., Sihota, S., Rowe, M. & Young, L. S. (1997). Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 14, 2899-2916.
14. Eliopoulos, A. G., Blake, S. M. S., Floettmann, J. E., Rowe, M. & Young, L. S. (1999). Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 73, 1023-1035.
15. Fielding, C. A., Sandvej, K., Mehl, A., Brennan, P., Jones, M. & Rowe, M. (2001). Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J Virol 75, 9129-9141.
16. Floettmann, J. E. & Rowe, M. (1997). Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation. Oncogene 15, 1851-1858.
17. Fries, K. L., Miller, W. E. & Raab-Traub, N. (1996). Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 70, 8653-8659.
18. Gires, O., Kohlhuber, F., Kilger, E. & 7 other authors (1999). Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 18, 3064-3073.
19. Gorski, J. (1990). HLA analysis by PCR/SSOPH. In The HLA System: a New Approach, pp. 73-78. Edited by J. Lee. New York: Springer-Verlag.
20. Hahn, P., Novikova, E., Scherback, L. & 7 other authors (2001). The LMP1 gene isolated from Russian nasopharyngeal carcinoma has no 30-bp deletion. Int J Cancer 91, 815-821.
21. Hammarskjöld, M. L. & Simurda, M. C. (1992). Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J Virol 66, 6496-6501.
22. Henderson, S., Rowe, M., Gregory, C., Croom-Carter, D., Wang, F., Longnecker, R., Kieff, E. & Rickinson, A. (1991). Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65, 1107-1115.
23. Henry, S., Sacaze, C., Berrajah, L., Karray, H., Drira, M., Hammami, A., Icart, J. & Mariame, B. (2001). In nasopharyngeal carcinoma-bearing patients, tumors and lymphocytes are infected by different Epstein-Barr virus strains. Int J Cancer 91, 698-704.
24. Hu, L.-F., Zabarovsky, E. R., Chen, F., Cao, S.-L., Ernberg, I., Klein, G. & Winberg, G. (1991). Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72, 2399-2409.
25. Huen, D. S., Henderson, S. A., Croom-Carter, D. & Rowe, M. (1995). The Epstein-Barr virus latent protein-1 (LMP-1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10, 549-560.
26. Itakura, O., Yamada, S., Narita, M. & Kikuta, H. (1996). High prevalence of a 30-base pair deletion and single-base mutations within the carboxy terminal end of the LMP-1 oncogene of Epstein-Barr virus in the Japanese population. Oncogene 13, 1549-1553.
27. Izumi, K. M. & Kieff, E. D. (1997). The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc Natl Acad Sci U S A 94, 12592-12597.
28. Izumi, K. M., McFarland, E. C., Ting, A. T., Riley, E. A., Seed, B. & Kieff, E. D. (1999). The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP but does not induce apoptosis or require RIP for NF-κB activation. Mol Cell Biol 19, 5759-5767.
29. Khanna, R., Burrows, S. R., Nicholls, J. & Poulsen, L. M. (1998). Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 28, 451-458.
30. Kieser, A., Kaiser, E. & Hammerschmidt, W. (1999). LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J 18, 2511-2521.
31. Li, S. N., Chang, Y. S. & Liu, S. T. (1996). Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 12, 2129-2135.
32. Lin, J.-C., Lin, S.-C., De, B. K., Chan, W.-P., Evatt, B. L. & Chan, W. C. (1993). Precision of genotyping of Epstein-Barr virus by polymerase chain reaction using three gene loci (EBNA-2, EBNA-3C, and EBER): predominance of type A virus associated with Hodgkin's disease. Blood 81, 3372-3381.
33. Lin, J.-C., Lin, S.-C., Luppi, M., Torelli, G. & Mar, E.-C. (1995). Geographic sequence variation of latent membrane protein 1 gene of Epstein-Barr virus in Hodgkin's lymphomas. J Med Virol 45, 183-191.
34. Lung, M. L., Chang, R. S., Huang, M. L., Guo, H.-Y., Choy, D., Sham, J., Tsao, S. Y., Cheng, P. & Ng, M. H. (1990). Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in southern China. Virology 177, 44-53.
35. Miller, W. E., Edwards, R. H., Walling, D. M. & Raab-Traub, N. (1994). Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol 75, 2729-2740.
36. Miller, W. E., Earp, H. S. & Raab-Traub, N. (1995). The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 69, 4390-4398.
37. Mitchell, T. & Sugden, B. (1995). Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 69, 2968-2976.
38. Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C. & Kieff, E. (1995). The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80, 389-399.
39. Murono, S., Inoue, H., Tanabe, T., Joab, I., Yoshizaki, T., Furukawa, M. & Pagano, J. S. (2001). Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A 98, 6905-6910.
40. Parker, K. C., Bednarek, M. A. & Coligan, J. E. (1994). Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152, 163-175.
41. Raab-Traub, N. (1992). Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol 3, 297-307.
42. Rickinson, A. B., Young, L. S. & Rowe, M. (1987). Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol 61, 1310-1317.
43. Sandberg, M., Hammerschmidt, W. & Sugden, B. (1997). Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol 71, 4649-4656.
44. Sandvej, K., Gratama, J. W., Munch, M., Zhou, X.-G., Bolhuis, R. L. H., Andresen, B. S., Gregersen, N. & Hamilton-Dutoit, S. (1997 . Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: identification of four variants among wild-type EBV isolates. Blood 90, 323-330.
45. Sung, N. S., Edwards, R. H., Seillier-Moiseiwitsch, F., Perkins, A. G., Zeng, Y. & Raab-Traub, N. (1998). Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China. Int J Cancer 76, 207-215.
46. Trivedi, P., Hu, L. F., Chen, F., Christensson, B., Masucci, M. G., Klein, G. & Winberg, G. (1994). Epstein-Barr virus (EBV -encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer 30A, 84-88.
47. Walling, D. M., Shebib, N., Weaver, S. C., Nichols, C. M., Flaitz, C. M. & Webster-Cyriaque, J. (1999). The molecular epidemiology and evolution of Epstein-Barr virus: sequence variation and genetic recombination in the latent membrane protein-1 gene. J Infect Dis 179, 763-774.
48. Wang, D., Liebowitz, D. & Kieff, E. (1985). An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43, 831-840.
49. Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A. & Kieff, E. (1990). Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64, 2309-2318.
50. Yoshizaki, T., Sato, H., Furukawa, M. & Pagano, J. S. (1998). The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci U S A 95, 3621-3626.